Last reviewed · How we verify

NCT01556802

Effect of Minocicline Use in Less Neurologic Sequels in Patients With Stroke

Status unknown Phase 1 Last updated 15 March 2012
What this trial tests

Phase 1 trial testing Minocicline in Stroke in 134 participants. Status unknown.

Timeline
1 October 2011
Primary endpoint
1 November 2011
1 January 2013

Quick facts

Lead sponsorHospital Universitario Hernando Moncaleano Perdomo
PhasePhase 1
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingtriple
Primary purposetreatment
Enrollment134
Start date1 October 2011
Primary completion1 November 2011
Estimated completion1 January 2013
Sites1 location across Colombia

Drugs / interventions tested

Conditions studied

Sponsor

Hospital Universitario Hernando Moncaleano Perdomo

Who can join

Adults 18 to 85, any sex, with Stroke or Brain Ischemia. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Sponsor's own description

The investigators will evaluate the National Institute of Health Stroke Scale/Score (NIHSS)in patients with stroke, and then give Minocycline 100mg po every 12 hours or placebo for five days, then perform periodic evaluations to determine the status and degree of neurological sequelae developed.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Stroke

Currently open trials in the same condition.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01556802.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing